Q2 Earnings Forecast for Korro Bio Issued By William Blair

Korro Bio, Inc. (NASDAQ:KRRO) – Equities researchers at William Blair cut their Q2 2025 earnings per share (EPS) estimates for Korro Bio in a report issued on Thursday, May 8th. William Blair analyst M. Minter now forecasts that the company will post earnings of ($3.11) per share for the quarter, down from their prior forecast of ($2.98). The consensus estimate for Korro Bio’s current full-year earnings is ($9.52) per share. William Blair also issued estimates for Korro Bio’s Q3 2025 earnings at ($3.03) EPS, Q4 2025 earnings at ($3.06) EPS, FY2025 earnings at ($11.70) EPS, FY2026 earnings at ($12.66) EPS, FY2027 earnings at ($13.46) EPS, FY2028 earnings at ($12.85) EPS and FY2029 earnings at $15.22 EPS.

A number of other equities analysts have also weighed in on the company. Oppenheimer lowered their price objective on Korro Bio from $155.00 to $90.00 and set an “outperform” rating on the stock in a research note on Tuesday. HC Wainwright lowered their price objective on Korro Bio from $115.00 to $100.00 and set a “buy” rating on the stock in a research note on Thursday, May 8th. Royal Bank of Canada lowered their price objective on Korro Bio from $105.00 to $95.00 and set an “outperform” rating on the stock in a research note on Wednesday, March 19th. Chardan Capital reissued a “buy” rating and set a $25.00 price objective on shares of Korro Bio in a research note on Tuesday. Finally, Cantor Fitzgerald raised Korro Bio to a “strong-buy” rating in a research note on Tuesday, April 29th. Six analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus target price of $104.63.

Korro Bio Stock Performance

NASDAQ KRRO opened at $15.55 on Monday. The stock’s fifty day moving average is $17.53 and its two-hundred day moving average is $33.59. The firm has a market capitalization of $146.03 million, a P/E ratio of -1.65 and a beta of 2.66. Korro Bio has a fifty-two week low of $11.13 and a fifty-two week high of $98.00.

Korro Bio (NASDAQ:KRRO) last issued its quarterly earnings results on Wednesday, May 7th. The company reported ($2.49) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($2.60) by $0.11. The firm had revenue of $2.55 million during the quarter, compared to analyst estimates of $0.13 million.

Institutional Investors Weigh In On Korro Bio

Several large investors have recently bought and sold shares of the stock. Deep Track Capital LP increased its holdings in Korro Bio by 2.9% during the 4th quarter. Deep Track Capital LP now owns 874,614 shares of the company’s stock worth $33,297,000 after purchasing an additional 24,614 shares during the period. Alliancebernstein L.P. purchased a new stake in Korro Bio during the 4th quarter worth about $26,870,000. Driehaus Capital Management LLC increased its holdings in Korro Bio by 220.3% during the 4th quarter. Driehaus Capital Management LLC now owns 494,905 shares of the company’s stock worth $18,841,000 after purchasing an additional 340,410 shares during the period. Point72 Asset Management L.P. increased its holdings in Korro Bio by 11.0% during the 4th quarter. Point72 Asset Management L.P. now owns 493,997 shares of the company’s stock worth $18,806,000 after purchasing an additional 49,147 shares during the period. Finally, Tri Locum Partners LP increased its holdings in Korro Bio by 125.3% during the 4th quarter. Tri Locum Partners LP now owns 144,216 shares of the company’s stock worth $5,490,000 after purchasing an additional 80,202 shares during the period. Hedge funds and other institutional investors own 13.18% of the company’s stock.

Korro Bio Company Profile

Korro Bio, Inc, a biopharmaceutical company, engages in the discovery, development, and commercialization of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases primarily in the United States. Its lead product candidate is KRRO-110 which is in preclinical trials for the treatment of Alpha-1 Antitrypsin Deficiency (AATD).